Stockreport

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Alterity Therapeutics Limited - American Depositary Shares  (ATHE) 
PDF MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology [Read more]